TECH Overview

Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.

Wall Street analysts forecast TECH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECH is66.14 USD with a low forecast of 60.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Bio-Techne Corp revenue for the last quarter amounts to 295.88M USD, decreased -0.39

Bio-Techne Corp. EPS for the last quarter amounts to 0.24 USD, increased 9.09

Bio-Techne Corp (TECH) has 3100 emplpoyees as of March 03 2026.

Today TECH has the market capitalization of 9.05B USD.